BCMA CAR-NK (Hrain Biotechnology)

N/A

Report date: 2024/04/12 20:03:58

Base Information

Drug NameBCMA CAR-NK (Hrain Biotechnology)
Drug Alias NameHR012
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionAnti-BCMA
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple MyelomaLeukemia, Plasma Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHrain Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHrain Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple MyelomaLeukemia, Plasma Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A